📢 Our paper is out in @diagnostic_mdpi. In 96 pts with AL cardiac amyloidosis, lower SBP, troponin >3× URL & advanced NYHA class independently predicted mortality. Adding SBP to Mayo 2012 modestly improved risk stratification 🫀
@mbeksac56 @AnkaraUni
A milestone achieved! 🎓
Today, I successfully defended my doctoral thesis and officially earned my #PhD I am grateful to everyone who supported me throughout this journey. On to the next chapter! @Ankaratip1945 @AnkaraUni
1
8
269
Delighted to chair the Oral Abstract Session on Immunotherapy in Multiple Myeloma at #EHA2026. Outstanding abstracts, inspiring discussions, and promising advances for our patients. @EHA_Hematology @AnkaraUni @EMN_EuMMnet
guldane seval retweeted
Replying to @EHA_Hematology
@EHA_Hematology @RobertoMinaMD @gdnsvl @ninashah33 Happy to participate in MONUMENTAL-3 being launched at #EHA2026 and NEJM simultaneously nejm.org/doi/full/10.1056/NE… another TCE and antiCD38 combo in RRMM
guldane seval retweeted
MonumenTAL-3 is out in NEJM 🍾
nejm.org/doi/full/10.1056/NE…
Tal-dara-pom and Tal-dara offer superior PFS and OS over DPd. Tal-based combos are a new SOC in 2line + RRMM
Congrats to the study team and the co-authors!
@PlasmaCellPete @mbeksac56 @gdnsvl @paurotero @mvmateos
guldane seval retweeted
CONGRESS | #ASCO26 | POSTER
Güldane Cengiz-Seval presents results from an analysis of the phase III DREAMM-8 trial, evaluating PFS2 outcomes by prior therapy in patients with relapsed/refractory #MultipleMyeloma treated with BPd (n = 155) or PVd (n = 147).
PFS2 benefit with BPd vs PVd was maintained across prior-therapy subgroups, including patients who were Len-refractory and anti-CD38-exposed/refractory (HR, 0.63; 95% CI, 0.36–1.12). In Len-refractory patients, median PFS2 was 41.7 vs 15.0 months, respectively (HR, 0.49; 95% CI, 0.35–0.68). Median PFS2 was numerically longer in patients who received novel therapies vs non-novel agents as first subsequent therapy (26.0 vs 20.1 months; HR, 0.61; 95% CI, 0.34–1.09).
Follow our live feed for more updates: bit.ly/4dBGu9i
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#mmsm #myeloma #MedEd #MedicalCongress @gdnsvl @AnkaraUni @AnkaraUni_en
guldane seval retweeted
amazing #ASCO2026 presenting practice changing data from Majestec9 with Teclistamab vs SOC while sharing the stage with Italian friends and colleagues @Dagostino_MD @LucaBertamini
Congrats to the maj9 team CTouzeau @HangQuach1 @dra_v_hungria @myelomaMD @thanosdimop @NBahlis
guldane seval retweeted
Replying to @met2026
@MET2026 @TheEBMT @TheEBMT_CTIWP second day is starting w post TCTmeeting Dr Ugur Sahin from Ankara chaired by Prf Hakan Göker and Namık Demir @gdnsvl
guldane seval retweeted
Replying to @TheEBMT
@TheEBMT @MET2026 @i_yakoub_agha is giving a openning lecture on innovation in SCT fifty year history
Honored to attend the Educational Workshop of the @Myeloma_Society in Belgrade @MyelomaBmsg
Great discussions and inspiring colleagues working together to advance myeloma research and patient care. @mbeksac56 @myelomaMD @NoopurRajeMD
guldane seval retweeted
#Myeloma Paper of the Day: Phase II EMN19 study of Dara-VCd in EMD pts shows overall heme ≥CR rate 47.5% (19/40; NDMM: 58.6%; RRMM: 18.2%); in CRs, MRD negativity 68.4% (13/19); median PFS 25.8 mos, significantly longer in pts achieving heme ≥CR: pubmed.ncbi.nlm.nih.gov/4152…. #mmsm
guldane seval retweeted
Türk Kemik İliği Transplantasyon Vakfı’nın bu harika yıllık toplantısı için teşekkür ederim. Mükemmel oturumlar, parlak tartışmalar ve genç bir izleyici kitlesiyle doluydu. Türk hematolojisinin geleceği parlak!
❤️🇹🇷❤️
@mbeksac56 @ativittta @eskazanae @gdnsvl
Excellent session on chronic GvHD at #MET2025 Inspiring, entertaining and practice changing talks delivered by @DrCCutler from @ASTCT
Take home message: the future needs to be biologically driven! @mbeksac56 @i_yakoub_agha @NicoGagelmann @TheEBMT
Outstanding talk by Prof. Charles Craddock on the FIGARO trial — clear, insightful, and clinically relevant.Time to rethink our transplant strategies. @BritSocHaem @TheEBMT @i_yakoub_agha @NicoGagelmann @mbeksac56
Soaking up the latest myeloma #mmsm insights at 6th @EMN_EuMMnet with an inspiring mentor @mbeksac56
Happy New Year 2025 from all of us at the @AnkaraUni Plasma Cell Disorders Clinical Trial Unit! 🎉 Wishing our colleagues, collaborators, and patients a year filled with health, progress, and groundbreaking advancements in research. Here’s to making a difference together!





























